Roche hands back rights to NewLink’s immunotherapy

9th June 2017 Uncategorised 0

Roche’s Genentech is handing back rights to NewLink Genetic’s investigational immunotherapy navoximod, pushing the latter’s stock down more than 30 percent.

More: Roche hands back rights to NewLink’s immunotherapy
Source: News